VICAL GETS $12 MILLION HIV VACCINE PRODUCTION ORDER TO SUPPORT NIH TRIALS

Vical has announced the receipt of approximately $12.1 million in production orders for multiple clinical lots of DNA vaccines against HIV for the Vaccine Research Center (VRC) at the NIH's National Institute of Allergy and Infectious Diseases, under a subcontract managed by SAIC-Frederick.

Production is scheduled to begin in the second half of 2005, with shipments anticipated in 2005 and 2006 in support of planned Phase II studies. The company has produced multiple DNA vaccines for the VRC against infectious disease targets including Ebola, severe acute respiratory syndrome and West Nile virus.